These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 18503958

  • 21. Outcome of heart transplants 15 to 20 years ago: graft survival, post-transplant morbidity, and risk factors for mortality.
    Roussel JC, Baron O, Périgaud C, Bizouarn P, Pattier S, Habash O, Mugniot A, Petit T, Michaud JL, Heymann MF, Treilhaud M, Trochu JN, Gueffet JP, Lamirault G, Duveau D, Despins P.
    J Heart Lung Transplant; 2008 May; 27(5):486-93. PubMed ID: 18442713
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation.
    Mullen JC, Oreopoulos A, Lien DC, Bentley MJ, Modry DL, Stewart K, Winton TL, Jackson K, Doucette K, Preiksaitis J, Halloran PF.
    J Heart Lung Transplant; 2007 May; 26(5):504-10. PubMed ID: 17449421
    [Abstract] [Full Text] [Related]

  • 24. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients.
    Opelz G, Naujokat C, Daniel V, Terness P, Döhler B.
    Transplantation; 2006 May 15; 81(9):1227-33. PubMed ID: 16699447
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Efficacy of low-dose OKT3 as cytolytic induction therapy in heart transplantation.
    Alonso-Pulpón L, Serrano-Fiz S, Rubio JA, Cavero MA, Silva L, Sánchez-Vegazo I, Burgos R, Montero CG, Maicas C, Kreisler M.
    J Heart Lung Transplant; 1995 May 15; 14(1 Pt 1):136-42. PubMed ID: 7727462
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A pharmacoeconomic comparison of antithymocyte globulin and muromonab CD3 induction therapy in renal transplant recipients.
    Brennan DC, Schnitzler MA, Baty JD, Ceriotti CS, Lowell JA, Shenoy S, Howard TK, Woodward RS.
    Pharmacoeconomics; 1997 Mar 15; 11(3):237-45. PubMed ID: 10165313
    [Abstract] [Full Text] [Related]

  • 29. Short-term versus long-term induction therapy with antithymocyte globulin in orthotopic liver transplantation.
    Soliman T, Hetz H, Burghuber C, Györi G, Silberhumer G, Steininger R, Mühlbacher F, Berlakovich GA.
    Transpl Int; 2007 May 15; 20(5):447-52. PubMed ID: 17343686
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. 20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients.
    Cantarovich M, Durrbach A, Hiesse C, Ladouceur M, Benoit G, Charpentier B.
    Transplantation; 2008 Dec 27; 86(12):1732-7. PubMed ID: 19104413
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.